<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Chronic inflammatory disease, such as atherosclerosis, nonalcoholic fatty liver disease (NAFLD) [
 <xref rid="B3-marinedrugs-17-00374" ref-type="bibr" class="xref">3</xref>], chronic obstructive pulmonary disease (COPD) [
 <xref rid="B4-marinedrugs-17-00374" ref-type="bibr" class="xref">4</xref>], inflammatory bowel disease (IBD) [
 <xref rid="B5-marinedrugs-17-00374" ref-type="bibr" class="xref">5</xref>], and retinal illnesses [
 <xref rid="B6-marinedrugs-17-00374" ref-type="bibr" class="xref">6</xref>], are responsible of pain, impaired function, and diminished quality of life, as well as, the associated high health-care costs and loss of productivity [
 <xref rid="B7-marinedrugs-17-00374" ref-type="bibr" class="xref">7</xref>].
</p>
